I liked the paper very much. It is generally well done and suggests an easy intervention that could reduce AD onset or progression without significant toxicity. Among the questions it raises are:
1.) How does the concentration of curcumin that is effective in the APPSw mice compare to that normally ingested in countries where curcumin is a staple?
2.) Can curcumin be given after the pathology has started, or does it need to be taken for a long time prior to symptoms?
3.) It would be helpful to compare the effects of curcumin on inflammatory oxidative markers in the APPSw mice with the effects of giving vitamin E, vitamin E and NSAIDs, as the authors argue that curcumin is more beneficial because it combines the properties of an antioxidant and NSAID.
View all comments by Rajiv Ratan